Physician profile
Hank C Yang
NPI 1356429831
$8,550.39
in general payments reported to CMS, 2019-2025
35 companies · $552 in 2025
The $552 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,290 · 2020: $2,153 · 2021: $112 · 2022: $691 · 2023: $720 · 2024: $1,034 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,272 · Education: $32.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,272.25 |
| Education | $32.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,568.26 | 2019-2025 | Lynparza, Imfinzi |
| Celgene Corporation | $1,768.27 | 2019-2022 | |
| Glaxosmithkline, LLC. | $358.99 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $318.13 | 2022-2025 | Fruzaqla, Iclusig, Alunbrig |
| Eisai INC. | $300.13 | 2020-2024 | |
| Hologic Sales and Service, LLC | $167.18 | 2022-2023 | Coolseal Generator |
| Beigene USA, INC. | $161.09 | 2022-2025 | Brukinsa |
| Pfizer INC. | $146.37 | 2019-2025 | |
| Janssen Biotech, INC. | $137.32 | 2022-2024 | Rybrevant, Erleada |
| Pharmacyclics LLC, An Abbvie Company | $125.00 | 2022 | |
| Incyte Corporation | $115.89 | 2019-2024 | Jakafi, Pemazyre, Monjuvi |
| Stemline Therapeutics INC. | $112.97 | 2019-2024 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $110.55 | 2019-2025 | Somatuline Depot, Onivyde |
| Puma Biotechnology, INC. | $109.18 | 2019-2020 | |
| Beone Medicines USA, INC. | $108.43 | 2025 | Brukinsa |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $102.32 | 2022-2024 | |
| Array Biopharma INC | $84.24 | 2022-2023 | Lorbrena, Braftovi, Mektovi |
| Lilly USA, LLC | $79.05 | 2019-2020 | |
| Syndax Pharmaceuticals, INC. | $71.00 | 2025 | |
| Morphosys, US INC. | $67.12 | 2021-2024 | Monjuvi |
| Jazz Pharmaceuticals INC. | $58.05 | 2020-2024 | |
| Genentech USA, INC. | $51.01 | 2022-2025 | Venclexta |
| Clovis Oncology, INC. | $47.54 | 2020 | |
| Rigel Pharmaceuticals, INC. | $44.88 | 2023 | Tavalisse, Rezlidhia |
| Mirati Therapeutics, INC. | $44.56 | 2023-2024 | Krazati |
| Kite Pharma, INC. | $44.36 | 2024 | Yescarta |
| Emd Serono, INC. | $40.39 | 2019-2020 | |
| Adc Therapeutics America, INC. | $38.76 | 2024 | |
| Verastem, INC. | $34.46 | 2019 | |
| Genmab U.S., INC. | $29.63 | 2024 | Epkinly |
| Taiho Oncology, INC. | $25.00 | 2022 | |
| Karyopharm Therapeutics INC. | $24.81 | 2022 | |
| Novocure INC. | $23.91 | 2023 | Optune |
| Daiichi Sankyo INC. | $19.37 | 2025 | Enhertu |
| Pharmaand Gmbh | $12.17 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hank Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.